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Abstract
Expression of matrix metalloproteinase-1 (MMP-1), an interstitial collagenase, plays a major role in cellular invasion during
development of gastric cancer, a leading cause of death worldwide. A single-nucleotide polymorphism (SNP) 21607 1G/2G
site of the MMP-1 gene promoter has been reported to alter transcription level. While the importance’s of other SNPs in the
MMP-1 promoter have not yet been studied in gastric cancer, our aim was to investigate MMP-1 gene promoter
polymorphisms and gastric cancer susceptibility in eastern Indian population. A total of 145 gastric cancer patients and 145
healthy controls were genotyped for MMP-1 21607 1G/2G (rs1799750) by PCR-restriction fragment length polymorphism
(RFLP), while MMP-12519 A/G (rs1144393), MMP-12422 T/A (rs475007), MMP-12340 T/C (rs514921) and MMP-12320 T/C
(rs494379) were genotyped by DNA sequencing. A positive association was found with MMP-1 2422 T/A SNP that showed
significant risk for regional lymph node metastasis (P= 0.021, Odd’s ratio (OR) = 3.044, Confidence intervals (CI) = 1.187–
7.807). In addition, we found a significant association with lower stomach tumor formation among gastric cancer patients
for three adjacent polymorphisms near the transcriptional start sites of [MMP-1 2422 T/A (P= 0.043, OR = 2.182, CI = 1.03–
4.643), MMP-1 2340 T/C (P= 0.075, OR = 1.97, CI = 0.94–4.158) and MMP-1 2320 T/C (P= 0.034, OR= 2.224, CI = 1.064–
40731)]. MMP-1 level in patients’ serum was correlated with MMP-1 promoter haplotypes conferring these three SNPs to
evaluate the functional importance of these polymorphisms in lower stomach tumor formation and significant correlation
was observed. Furthermore, MMP-1 2519 A/G polymorphism displayed poor cellular differentiation (P= 0.024, OR= 3.8,
CI = 1.69–8.56) attributing a higher risk of cancer progression. In conclusion, MMP-1 proximal promoter SNPs are associated
with the risk of lower stomach tumor formation and node metastasis in eastern Indian population.
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Introduction
Gastric cancer is one of the leading causes of cancer related
death in the world [1]. On a global scale, gastric cancer (GC)
accounts for approximately 800,000 deaths annually. More than
70% of GC cases occur in developing countries and half the world
total occurs in Eastern Asia [1]. It is a leading problem in north-
eastern and southern states of the Indian subcontinent [2]. The
incidence of gastric cancer varies from country to country,
probably as a result of genetic, epigenetic and environmental
factors. Helicobacter pylori infection is considered as a major risk
factor in the development of gastric cancer especially cancer in the
lower part (noncardia) of the stomach [3]. A combined analysis of
12 studies of H. pylori and gastric cancer estimated that the risk of
adenocarcinoma in non-cardia regions of the stomach was nearly
six times higher for H. pylori-infected people than for uninfected
people [3].
Recent studies demonstrate that, carcinogenesis is a multi-
cellular and multi-stage process in which destruction of the tissue
microenvironment is a requisite for conversion of normal tissue to
tumor [4]. Hence, molecular analysis of the tissue microenviron-
ment and its deregulation during neoplasia is a key step to know
the mechanisms of malignancy. Matrix metalloproteinases
(MMPs), produced by both tumor and normal cells, alter the
microenvironment by degrading extracellular matrix, and subse-
quent cellular signals lead to the early stages of tumor formation
[5]. Several of the MMPs have the unique ability to degrade the
interstitial collagens (e.g. I, II, and III), the body’s most abundant
proteins. MMP-1 is the most ubiquitously expressed interstitial
collagenase [6] and its overexpression is associated with several
pathological conditions, including tumor invasion and metastasis
[7]. The overexpression of MMP-1 mRNA has been demonstrated
in a variety of cancers such as gastric cancer, colorectal cancer and
esophageal cancer [8–12]. Overexpression of MMP-1 protein is
associated with poor prognosis of esophageal cancer and colorectal
cancer [10,11]. This MMP-1 overexpression may be attributed to
the juxtaposition of transcription factor binding sites and
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cooperativity among the factors that bind to these sites within the
promoter region of the MMP-1 gene [13].
The promoter region of MMP-1 contains a guanine insertion/
deletion polymorphism (1G/2G polymorphism) at position 21607
which generates the sequence 59-GGA-39 which has a 2G allele.
The presence of a 2G polymorphism could increase transcriptional
activity of endogenous MMP-1 because the guanine insertion
creates a binding site for a member of the Ets transcription factor
family. The 2G allele may contribute to increased invasiveness of
endometrial carcinomas, to the development of ovarian cancer,
lung cancer, and colorectal cancer [14–21].
Studies in several other genes have provided a new paradigm in
which the transcription of a gene is more likely to be influenced by
multiple polymorphisms located in the promoter region which act
in concert to exert a haplotype effect [22,23]. Several other single
nucleotide polymorphisms (2519A/G, 2422T/A, 2340C/T,
and 2320C/T) in the MMP-1 gene promoter have recently been
identified [24]. Functional effects of these polymorphisms on the
MMP-1 gene promoter activity were assessed in cell lines of
melanoma (A2058 and A375), breast cancer (MCF7 and MDA-
MB-231), lung cancer (A549 and H69), and colorectal cancer
(HT-29, SW-620) by comparing the promoter strengths of the 10
most common haplotypes derived from these polymorphisms [24].
Although the enhanced expression of MMP-1 was associated with
local invasion and poor prognosis in gastric cancer [25], the role of
the MMP-1 promoter SNPs and their haplotypes in the
development of gastric cancer is currently unknown in any human
population.
In the present study, we conducted a hospital-based case-control
study to explore the association of the MMP-1 gene promoter
SNPs [21607 1G/2G (rs1799750) (MMP-1.1), 2519A/G
(rs1144393) (MMP-1.2), 2422T/A (rs475007) (MMP-1.3), 2
340C/T (rs514921) (MMP-1.4), and 2320C/T (rs494379)
(MMP-1.5)] and their haplotypes with the risk of gastric cancer
development in an eastern Indian population. We also explored
the relationship between the polymorphisms and the clinicopath-
ological factors among gastric cancer patients. The study
demonstrated the putative association of MMP-1.3, MMP-1.4,
and MMP-1.5 polymorphisms with the risk of lower stomach
tumor formation in gastric cancer. The functional importance of
MMP-1 polymorphisms in lower stomach tumor formation was
confirmed by haplotype effects of these polymorphisms on MMP-1
expression levels in serum. However, no association with the
occurrence of gastric cancer was found for any of the above five
SNPs of the MMP-1 promoter and their resultant haplotypes.
Materials and Methods
Study Subjects: Eastern Indian Case-control Cohort
The eastern Indian case-control cohort consisted of 145 gastric
cancer cases and 145 control individuals. The study protocols
(2008–2014) were approved by the Ethical Review Boards of the
Saroj Gupta Cancer Center and Research Institute, Kolkata,
Department of Gastric Surgery, Medical College and Hospital,
Kolkata, IPGMER, Kolkata hospitals and the Human Ethics
Committee of the Indian Institute of Chemical Biology, Kolkata,
India. All patients with a clinical diagnosis of gastric cancer
attending the hospital Departments of Gastro-oncology of the
Saroj Gupta Cancer Center and Research Institute, Kolkata, the
Department of Gastric Surgery, Medical College and Hospital,
Kolkata and the IPGMER, Kolkata during June 2008 to May
2013 were identified from hospital registries and contacted during
follow up investigations. All participants gave written informed
consent for participation. Patients’ demographics, symptoms and
tumor grading were recorded and blood samples collected after
taking a clinical history and performing clinical and endoscopic
examinations. Histological tumor typing was determined on the
basis of biopsies or resected specimens. The exclusion criteria
included previous history of other metastasized cancer except
gastric cancer. Possibility of peptic ulcer without having any
cancerous lesion had been excluded by histopathology of stomach
lesion. The diagnosis of gastric cancer and TNM staging was
based on generally accepted clinical, histological, radiological and
immunofluorescence findings and that of the American Joint
Committee on cancer (AJCC) and the International Union
Against Cancer (UICC) criterion [25]. Individuals who were
formerly or who currently have been addicted to tobacco for at
least 2 years were defined as tobacco addicted. Persons visiting
these hospitals for a routine checkup and who were without a
history or diagnosis of any cancer or genetic diseases were also
asked to participate and volunteer to donate blood for the study.
These subjects were considered healthy controls. All of the cancer
patients and control subjects were unrelated and of Indian
nationality from West Bengal or the surrounding eastern Indian
states. This population was considered representative of an eastern
Indian population.
DNA Extraction and Serum Collection
From each subject, 5 ml of venous blood were drawn aseptically
into vacutainer tubes (Qiagen, USA) containing EDTA and stored
at 4uC prior to genomic DNA extraction. Genomic DNA was
extracted from 3.5 ml of whole-blood within two weeks following
sampling using a QIAamp DNA Blood Midi Kit (Qiagen, USA)
according to the manufacturer’s protocol. Immediately following
blood collection, additional1.5 ml of whole blood was centrifuged
at 1800 g for 5 min to obtain the serum fraction. Serum samples
were stored at 280uC until analysis.
Primers and PCR Amplification of the Promoter Region of
MMP-1 Genes
Primers were designed with FastPCR software (http://www.
biocenter.helsinki.fi) so as to amplify promoter regions of the
MMP-1 gene in order to analyze polymorphisms by sequencing
(Table 1). PCR was performed in a PCR SPRINT Thermal
Cycler (Thermo Electron Corporation, Japan). The target
sequence was amplified in a 25-ml reaction volume containing
10–20 ng of genomic DNA, 0.2 mM dNTP, 10 mM Tris-HCl
(pH 8.3), 50 mM KCl, 2 mMMgCl2, 0.3 mM of each primer, and
1.0 units of Taq DNA polymerase (Fermentas Taq DNA
polymerase, Fermentas, USA). The PCR amplification was carried
out with 35 cycles of denaturation at 94uC for 30 s, annealing at
58uC-59uC for 1 min (Table 1) and followed by extension at 72uC
for 30 s after the initial activation step of 94uC for 5 min. PCR
fragments were analyzed comparing with 100 bp DNA ladder
(Fermentas, USA) on an ethidium bromide stained 1.5% agarose
gel (Cat No. 014011, Sisco Research Laboratories, India) run for
60 min at 100 V.
Genotyping
For genotyping by sequencing, any unincorporated dNTPs were
dephosphorylated and unincorporated primers were removed
from the PCR product by shrimp alkaline phosphatase (Fermen-
tas, USA) and exonuclease-I enzyme (Fermentas, USA). PCR
products were used for sequencing with BigDyeH Terminator v3.1
Cycle Sequencing Kit (Applied Biosystems, USA) and sequenced
using a ABI PRISM 3100 genetic analyzer (Perkin-Elmer ABI,
Foster City, Calif.) according to the manufacturer’s protocol. The
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PCR amplicon was sequenced in both directions with forward and
reverse PCR primers eliminating the possibility of compression
artifacts. Sequencing chromatograms were analyzed using Se-
quence Scanner Software v1.0 (Applied Biosystems, USA) to
analyze alterations of the nucleotides and thus genotypes.
The MMP-1.1 1G/2G polymorphism was genotyped by PCR-
restriction fragment length polymorphism (RFLP) method using
AluI enzyme (New England BioLabs, Inc. (NEB); Ipswich, MA), as
described previously [26].
Enzyme-Linked Immunosorbent Assay (ELISA)
Serum MMP-1 protein level (pro and active) in patients with
upper stomach cancer with non risk haplotypes, and in lower
stomach cancer with risk haplotypes (contains one or more risk
alleles) were compared using a commercially available MMP-1
ELISA kit (ab10063, Abcam, USA), according to the manufac-
turer’s instruction. Serum samples were diluted (1:5 v/v) in assay
diluent provided in the kit. Briefly, 100 ml of the standards, blanks
and diluted serum sample were pipetted into the anti-human
MMP-1 precoated 96-well plate provided within the kit and
incubated for 2.5 hours at 37uC. After several washes, biotinylated
anti-human MMP-1 antibody (diluted 1:1000) was added to the
wells and the plate was incubated for 1 hour at room temperature.
After washing away unbound biotinylated antibody, HRP-
conjugated streptavidin is pipetted to the wells. The plate was
again incubated for 45 min. After extensive washing, 100 ml of the
substrate tetramethylbenizidine was pipette into each well, and the
plate was incubated for 30 min in the dark at room temperature
(25uC). A stop solution was added upon completion. Each sample
was tested in duplicate. The absorbance values of the blanks,
samples, and standards were read on a microplate reader at a
wavelength of 450 nm. The level of MMP-1 protein in the samples
was obtained by comparison with the standard curve, generated
from standard supplied by the manufacture. The minimum
detectable level of MMP 1 was 8 pg/ml.
Statistical Analysis
Statistical analysis was performed using the SPSS software
(version 16.0J. SPSS, Inc., Chicago, IL, USA). Significant
differences between age at interview for controls and age at
diagnosis for cancer cases were assessed using the Student’s t-test
for comparison of means using GraphPad InStat3 software
(GraphPad Software, Inc., San Diego California USA). Hardy–
Weinberg equilibrium (HWE) analyses were performed to
compare observed and expected allele frequencies using a chi-
square test for controls to ensure that each marker was in
equilibrium (p.0.05). The minor allele frequency (MAF) (–model
option) and HWE (–hardy option) for each SNP was estimated from
the control population using Plink v0.99 [27]. Case-control data
were analyzed using two-sided 2-by-2 or 2-by-3 contingency tables
according to the genotype by the Pearson chi-square test. The
odds ratio (OR) and 95% confidence interval (CI) of the genotypes
were calculated from a multivariate logistic regression model
adjusted for age (continuous variable), sex and tobacco addiction.
In this study, we defined that the 1G allele of the 1G-1607 2G
SNP, the A allele of the A-519G SNP, the A allele of the T-422A
SNP, the T allele of the T-340C SNP and the T allele of the T-
320C SNP were reference alleles. The results were evaluated with
above alleles as a reference using the multinomial logistic
regression model. In analyzing the relationship between the SNP
genotypes and disease status of GC, the stage of cancer,
histological classification and depth of tumor invasion were
transformed to binary data (Stage I+II vs. stage III+IV, well-
differentiated+moderately-differentiated vs. Poorly-differentiated,
and T1+T2 vs. T3+T4). The relationship between genotype
distributions and tumor depth or stage was also examined using a
multinomial logistic regression model adjusted for age (continuous
variable), sex and tobacco addiction as a potential confounding
factor. Haplotype frequencies were analyzed using the program
Haploview (ver. 4.1, Broad Institute, Chembridge, USA) [28]. All
results were considered statistically significant if the p value was ,
0.05. A post hoc power calculation has been performed to test the
statistical power of the present study according to the method of
Schlesselman, JJ [29].
Results
Description of the Study Population
The study population consisted of 145 gastric cancer patients
having 112 (77.2%) males and 33 (22.8%) females with an age
range of 42.6–65.8 years, as well as 145 control subjects having 81
(55.9%) males and 64 (44.1%) females with an age range of 34.5–
62.5 years. Patients and control subjects were derived from the
same geographic location and are representative of an eastern
Indian population. There were statistically significant differences
Table 1. PCR primers used for polymorphism analysis.
Polymorphisms Primer sequence (59-39) Ta (6C) Product size Screening method used
MMP-1 21607 1G/2G ACATTGCAGGATGTGCAGGCTCTT (F) 58 782 bp Sequencing
CTTGGGTACTGGTGACCGGTGTCA (R)
MMP-1 21607 1G/2G TGACTTTTAAAACATAGTCTATGTTCA (F) 58.5 269 bp PCR-RFLP
TCTTGGATTGATTTGAGATAAGTCATAGC (R)
MMP 1 2519 A/G TACAGGTGCATGACTCCATGCTTG (F) 58 885 bp Sequencing
TCTAGAGTCGCTGGGAAGCTGTGA (R)
MMP-1 2422 T/A TACAGGTGCATGACTCCATGCTTG (F) 58 885 bp Sequencing
TCTAGAGTCGCTGGGAAGCTGTGA (R)
MMP-1 2340 T/C TACAGGTGCATGACTCCATGCTTG (F) 58 885 bp Sequencing
TCTAGAGTCGCTGGGAAGCTGTGA (R)
MMP-1 2320 T/C TACAGGTGCATGACTCCATGCTTG (F) 58 885 bp Sequencing
TCTAGAGTCGCTGGGAAGCTGTGA (R)
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in the distribution of gender (p,0.001) and age (p,0.0001)
between patients and controls. Also, significantly more tobacco-
addicted individuals (p,0.0001) were present among patients
(68.3%) compared with controls (28.3%). So, in the course of risk
estimation, an age, sex and addiction-adjusted Odds ratios were
calculated.
Detection of Single Nucleotide Polymorphisms in the
MMP-1 Promoter
Naturally occurring, common sequence variants of the MMP-1
gene promoter in cases and controls were searched by direct DNA
sequencing. Alignment of sequence chromatogram with the
MMP-1 gene promoter contig sequence (Genebank accession
no- AF023338) confirmed the SNP positions at 21607 (1G/2G,
i.e., G insertion/deletion), 2519 (A/G), 2422 (T/A), 2340 (T/C)
and 2320 (T/C) (Figure S1 in File S1). MMP-1.1 genotyping by
PCR-RFLP was then performed among the gastric cancer patients
and controls. Figure S1A (File S1) shows a typical PCR-RFLP
pattern. The 269 bp target region of the MMP-1 gene promoter
was PCR-amplified and digested with AluI, which cleaved the 1G
allele to generate two fragments of 241 bp and 28 bp. The 2G
allele did not digest with AluI. Heterozygous genotype showed
three bands of 269 bp, 241 bp and 28 bp (Figure S1A in File S1).
MMP-1.2, MMP-1.3, MMP-1.4) and MMP-1.5 were genotyped
by DNA sequencing (Figure S1B in File S1). The MMP-1.1
genotype analysis by DNA sequencing was restricted to a pilot
study as well as for 10% of the population for rechecking. All
genotyping was performed among 145 patients and 145 controls.
Association between Individual SNPs of MMP-1 Promoter
and Gastric Cancer Risk
The genotype distributions of MMP-1 polymorphisms were
consistent with the Hardy–Weinberg equilibrium (HWE). The
study would have reached a power of 80% (Z-alpha = 1.645, for
alpha= 0.05) with 145 cases, case control ratio of 1.0 and 10%
exposed control to the risk allele having OR of 2.31.
MMP-1.1 polymorphism showed no significant difference in
distribution of genotypes (1G1G vs. 1G2G, 2G2G and 1G2G+
2G2G) between patients and controls (p=0.430, p=0.465 and
p=0.411 respectively). Also, the allele frequency distribution (1G
vs. 2G) was not significant between patients and controls
(p=1.000), and thus did not confer any risk for gastric cancer
development (Table 2). It is also noteworthy that the 2G allele was
the major allele in this population and we took it as a risk allele as
many other studies have previously considered it a risk allele
[14,30,31].
In gastric cancer patients, the frequency of the MMP-1.2 AG,
GG and AG+GG genotypes were not significantly different from
healthy controls (p=0.603, p=0.506 and p=0.510 respectively)
and thus did not confer any significant risk for gastric cancer. Also,
the allele frequency (A vs. G) in cancer patients were not
significantly differed from healthy controls (p=0.337) and did not
confer risk for gastric cancer development (Table 2).
The genotype frequency distribution, (AA vs. TT, TA and TA+
TT) of the MMP-1.3 polymorphism in the patient population was
not significantly different from healthy controls (p=0.626,
p=0.999 and p=0.806 respectively) and thus did not confer any
significant risk for gastric cancer. Also, the allele frequency (T vs.
A) distribution in cancer patients and controls were not significant
(p=0.927) (Table 2).
For patient MMP-1.4 polymorphism, genotypes (TT vs. TC,
CC and TC+CC) showed a similar distribution to that seen in
controls (p=0.474, p=0.424 and p=0.388 respectively) showing
no association for gastric cancer risk. Also, the distribution of allele
frequency (T vs. C) in patients and controls was not statistically
different (p=0.357), further showing the absence of any associa-
tion with gastric cancer risk (Table 2).
MMP-1.5 polymorphism genotype frequencies (TT vs. TC, CC
and TC+CC) in patients was similarly distributed to that of
controls (p=0.329, p=0.358 and p=0.228 respectively) showing
no significant risk for gastric cancer. Also, the distribution of allele
frequency (T vs. C) in both patients and controls was not
significantly different (p=0.469) (Table 2).
Association between Individual SNPs of MMP-1 as well as
Demographic and Clinicopathological Features at the
Time of Gastric Cancer Diagnosis
Associations were examined between each polymorphism and
the demographic and clinicopathological features of gastric cancer
patients and controls (Table 3). MMP-1.1, MMP-1.2, MMP-1.3,
MMP-1.4 and MMP-1.5 polymorphisms did not play any role in
determining gastric cancer risk for any age group, gender or
tobacco-addiction status.
MMP-1.1 and MMP-1.2 polymorphisms did not confer any
significant risk for tumor location or degree of tumor progression
in gastric cancer (Table 3). However patients carrying combina-
tion of AG and GG genotype of MMP-1.2 polymorphism were
significantly distributed among histological subtypes of cancer and
showed significantly greater risk for poorly differentiated (PD)
carcinomas (p=0.001, OR=3.803, CI = 1.69–8.56) (Table 3).
For MMP-1.3 polymorphism, patients carrying combination of
TA and TT genotypes were at more risk of lower stomach cancer
(lower & middle body, antrum and pylorus of stomach) (p=0.043,
OR=2.18, CI = 1.03–4.64). Also, the combination of TA and TT
genotypes were found more frequently in gastric cancer patients
with 10 or more metastatic lymph nodes (p=0.021, OR=3.044,
CI = 1.187–7.807), suggesting that the T allele had a detrimental
effects on gastric cancer progression and early metastasis (Table 3).
For MMP-1.4 polymorphism, the distribution of TC and CC
genotypes among patients with different tumor locations in the
stomach was close to reaching a statistical significant association
with the risk of lower stomach cancer (p=0.075, OR=1.969,
CI = 0.94–4.15) (Table 3). Contradictory to MMP-1.3 polymor-
phism, patients carrying a combination of TC and CC genotypes
gave protection against regional lymph node metastasis (p=0.026,
OR=0.34, CI = 0.13–0.88) in addition to distant metastasis
(p=0.061, OR=0.49, CI = 0.24–1.03) of gastric cancer (Table 3).
For MMP-1.5 polymorphism, a combination of TC and CC
genotypes showed a significant association with location of
stomach tumor. Patients carrying a combination of TC and CC
genotypes were at more risk of lower stomach cancer (p=0.034,
OR=2.22, CI = 1.06–4.07) (Table 3).
In stratification analysis for SNPs and lower stomach tumor
formation, the study would have reached a power of 80% (Z-
alpha= 1.645, for alpha= 0.05) with 89 lower stomach cases,
lower stomach and upper stomach sample ratio of 0.505 and 35%
exposed upper stomach patients to the risk allele having OR of
2.5.
Genotype Frequency at Two Linked Loci of MMP-1 SNPs
and Risk to Gastric Cancer
To evaluate the combined effects of two linked loci on the risk of
cancer, as individual SNPs did not confer risk for gastric cancer
development, the combined genotype frequencies were compared
in patients and controls. Distributions of paired loci frequencies for
adjacent polymorphisms were observed with increasing order of
Association of MMP1 SNPs with Lower Stomach Cancer
PLOS ONE | www.plosone.org 4 February 2014 | Volume 9 | Issue 2 | e88040
variant allele and associations were examined. There was no dose
dependent association observed, the number of variant allele was
increased for any combination of adjacent paired loci (Table 4).
Linkage Disequilibrium between the SNPs of MMP-1
Promoter and Haplotype Frequencies with the
Susceptibility to Gastric Cancer
All the polymorphisms in the MMP-1 gene promoter were
assessed for linkage disequilibrium (LD) between the polymor-
phisms and to identify common haplotypes present in the patient
and control cohorts. The region showed low to substantial LD
between the polymorphisms, except MMP-1.4 and MMP-1.5
which were in complete LD in the case-control study cohort
(Figure 1) (The linkage disequilibrium block definitions were based
on the method of Gabriel et al.) [32]. Sixteen haplotypes were
identified with a frequency higher than 1% both in control and
patient population, including all the five markers covering the
MMP-1 gene promoter. The extended haplotype frequency
distributions of MMP-1 polymorphisms were not significant
between gastric cancer patients and controls and none of these
haplotypes conferred risk for gastric cancer occurrence (data not
shown).
Table 2. Analysis of association between MMP-1 SNPs and the risk of occurrence of gastric cancer.
Genotype GC Patient Controls OR 95% CI P value
n % N %
MMP-1.1 (21607 1G/2G) 145 145
1G1G 23 15.9 20 13.8 1 (Ref)
1G2G 66 45.5 72 49.7 0.742 0.353–1.559 0.430
2G2G 56 38.6 53 36.6 0.746 0.340–1.637 0.465
1G2G+2G2G 122 84.1 125 86.3 0.742 0.364–1.511 0.411
1G allele 112 38.6 112 38.6 1 (Ref)
2G allele 178 61.4 178 61.4 1.000 0.716–1.397 1.000
MMP-1.2 (2519 A/G) 145 145
AA 91 62.8 100 69.0 1 (Ref)
AG 49 33.8 41 28.3 1.154 0.672–1.982 0.603
GG 5 3.4 4 2.8 1.640 0.382–7.047 0.506
AG+GG 54 37.2 45 31.0 1.194 0.705–2.020 0.510
A allele 231 79.7 241 83.1 1 (Ref)
G allele 59 20.3 49 16.9 1.256 0.826–1.911 0.337
MMP-1.3 (2422 T/A) 145 145
TT 17 11.7 17 11.7 1.221 0.547–2.725 0.626
TA 53 36.6 51 35.2 1.000 0.581–1.722 0.999
AA 75 51.7 77 53.1 1 (Ref)
TA+TT 70 48.3 68 46.9 1.065 0.646–1.755 0.806
T allele 87 30 85 29.3 1.034 0.724–1.476 0.927
A allele 203 70 205 70.7 1 (Ref)
MMP-1.4 (2340 T/C) 145 145
TT 69 47.6 78 53.8 1 (Ref)
TC 64 44.1 57 39.3 1.209 0.719–2.032 0.474
CC 12 8.3 10 6.9 1.499 0.556–4.043 0.424
TC+CC 76 52.4 67 46.2 1.246 0.757–2.051 0.388
T allele 202 69.7 213 73.4 1 (Ref)
C allele 88 30.3 77 26.6 1.205 0.839–1.73 0.357
MMP-1.5 (2320 T/C) 145 145
TT 73 50.3 67 46.2 1 (Ref)
TC 61 42.1 64 44.1 0.769 0.454–1.303 0.329
CC 11 7.6 14 9.7 0.650 0.259–1.631 0.358
TC+CC 72 49.7 74 53.8 0.734 0.443–1.214 0.228
T allele 207 71.4 198 69.3 1 (Ref)
C allele 83 28.6 92 31.7 0.863 0.605–1.231 0.469
Adjusted OR calculated for age, sex and addiction, by binary logistic regression model using SPSS v16.0 software. P value is for x2 test showing the significance of
difference in the distributions of the genotypes and alleles between patients and controls. OR =Odds ratio, CI = Confidence Interval, Ref = Reference genotype or allele
to calculate OR.
doi:10.1371/journal.pone.0088040.t002
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Functional Haplotype Effects of MMP-1 Polymorphisms’
on Lower Stomach Tumor Formation
Sixteen haplotypes were identified with a frequency higher than
1% and categorized by increasing order of polymorphic variant
alleles and analyzed for gene-dosage effect (Table S1 in File S1).
The difference in the haplotype frequency was significant between
lower stomach gastric cancer patients and upper stomach gastric
cancer patients as the number of polymorphic variant alleles were
increased resulting in the increase of risk for lower stomach gastric
cancer development with highest OR of 2.155, 95% CI= 1.317–
3.526, P= 0.0028, x2 = 9.52 for combined haplotypes containing 4
risk alleles (Table 5).
In order to investigate the impact of MMP-1 promoter
polymorphisms on the gene function, we compared serum
MMP-1 level by serum ELISA in patients having lower stomach
cancer with combined risk haplotypes (having at least any one risk
allele) vs. upper stomach cancer with the reference haplotype (1G-
Table 4. Distribution of MMP-1 paired loci polymorphisms
with increasing order of variant alleles and association with
the gastric cancer risk.
MMP-1.1-1.2 Con Patient OR 95% CI P
0 13 (9.0) 16 (11.0) 1 (Ref)
1 49 (33.8) 37 (25.5) 0.529 0.201–1.390 0.286
2 71 (49.0) 76 (52.5) 0.576 0.231–1.431 0.329
3 12 (8.3) 16 (11.0) 0.727 0.231–2.285 0.798
4 0 0 *
MMP-1.2-1.3
0 49 (33.8) 45 (31.0) 1 (Ref)
1 67 (46.2) 64 (44.2) 0.948 0.537–1.674 0.885
2 20 (13.8) 26 (17.9) 1.04 0.501–2.157 1
3 9 (6.2) 10 (6.9) 0.8 0.300–2.131 0.803
4 0 0 *
MMP-1.3-1.4
0 45 (31.0) 39 (26.9) 1 (Ref)
1 54 (37.2) 57 (39.3) 0.984 0.535–1.815 1
2 30 (20.7) 31 (21.4) 0.985 0.486–1.999 1
3 16 (11.0) 16 (11.0) 0.848 0.363–1.98 0.829
4 0 2 (1.4) 0.53 0.083–3.373 0.653
MMP-1.4-1.5
0 27 (18.6) 25 (17.2) 1 (Ref)
1 67 (46.2) 69 (47.6) 0.936 0.468–1.873 1
2 51 (35.2) 51 (35.2) 0.861 0.419–1.768 0.718
3 0 0 *
4 0 0 *
OR, odds ratio; CI, confidence interval; Ref, reference.
0 = no risk allele for both loci, 1 = one risk allele for any one loci, 2 = two risk
allele for both the loci, 3 = one risk allele for any one locus and two risk allele for
another locus, 4 = All risk allele for both the loci.
Adjusted OR calculated for age, sex, addiction, by binary logistic regression
model using SPSS v16.0 software.
P value is for x2-test showing the significance of difference in the distributions
of the variant alleles between patients and controls.
Values in bold indicate positive significance (P,0.05).
No risk allele for both the gene was taken as reference to calculate OR.
(*) OR not calculated because of very low frequency in both control and patient
population.
doi:10.1371/journal.pone.0088040.t004
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Figure 1. Gene map and LD structure of MMP-1 promoter locus. (A) SNP positions in the gene map of MMP-1 gene (prepared using NCBI
sequence viewer) in human chromosome 11. Different color schemes are assigned to show each SNP position in the map by marking the map
according to the reference assembly (HuRef NCBI Build 36.7) position of the SNP in the chromosome. The number in different colored boxes indicates
the SNP alias number used in our study. (B) LD structure of MMP-1 promoter locus SNPs. Linkage disequilibrium plots follows the GOLD heat map
Haploview 4.2 color scheme. Block definition is based on the method of Gabriel et al. [32]. Haploview plot of MMP-1 SNPs genotyped in 290 subjects
(145 patients and 145 controls common for all SNPs studied) in our study. Numbers in squares are pair wise D’ values between SNPs.
doi:10.1371/journal.pone.0088040.g001
Table 5. Association of increasing order of MMP-1 polymorphic variant alleles in haplotypes with Lower stomach gastric cancer
risk.
Haplotype Upper Stomach Lower Stomach OR 95% CI P x2 (Pearson)
0 0.138 0.091 Ref
1 0.336 0.379 1.711 1.264–2.315 0.0005 12.22
2 0.328 0.298 1.378 1.013–1.874 0.0439 4.18
3 0.159 0.177 1.688 1.201–2.373 0.0027 9.15
4 0.038 0.054 2.155 1.317–3.526 0.0028 9.52
5 0 0
Haplotypes order as MMP-1.1-MMP-1.2-MMP-1.3-MMP-1.4-MMP-1.5.
(a) two sided x2 Association P value, OR =Odds ratio, CI = Confidence Interval, Ref = Reference haplotype to calculate OR. Other possible combinations of linked loci are
omitted because of null frequency in the population. Haplotype frequency and haplotype association test performed using Haploview4.2 software. Haplotype numbers
denote the number of risk allele(s) present in the haplotypes.
doi:10.1371/journal.pone.0088040.t005
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A-A-T-T). The serum MMP-1 protein concentration was almost
1.5 fold higher in patients with lower stomach cancer (n = 54) (with
combined risk haplotypes) than patients with upper stomach
cancer (n = 15) (with reference haplotype; p = 0.024), suggesting
the functional importance of these SNPs in the regulation of
MMP-1 gene expression and there by influencing the lower
stomach carcinogenesis process (Figure 2). The analysis has been
repeated and confirmed upon log transforming the data (Figure S2
in File S1).
Discussion
Although MMPs are not oncogenic or mutagenic, they alter the
microenvironment and may affect the process of carcinogenesis
and its histology, and appear to be induced at the level of
transcriptional activation [33]. Being a member of MMP family,
MMP-1 has been reported to play an important role in cancer
invasion through overexpression, which is associated with metas-
tasis and poor prognosis in esophageal cancer, ovarian cancer,
cutaneous malignant melanoma, colorectal cancer and gastric
cancer [11,15,16,25,34]. Diffuse types of gastric cancer are usually
characterized by an abundant deposition of collagen fibers,
possibly requiring higher levels of MMP-1 expression for proper
tissue remodeling of the microenvironment [30]. The genetic
background has been suggested to play an important role in the
incidence and progression of gastric cancer [30]. In addition, some
polymorphic genes encoding metabolic enzymes and cell cycle
regulators, such as methylene tetrahydrofolate reductase,
NADPH: quinone oxidoreductase and Cyclin D1 have been
documented to confer a susceptibility to gastric cancer [35–37].
Therefore, polymorphic genes, alone, in combination with others
or through interaction with exogenous risk factors, may be used as
predicative parameters for screening individuals at a high risk of
gastric cancer.
To the best of our knowledge, this study of the association of
MMP-1 variants and the risk of gastric cancer development and
progression in an eastern Indian population is the first of its kind
with a focus on a 21607 1G/2G polymorphism (MMP-1.1), and
an additional four polymorphisms between this SNP and the
transcription start site. MMP-1 promoter region functional
polymorphisms responsible for its expressional alterations have
been correlated with various disease processes. Despite this, in our
study MMP-1.1 polymorphism and additionally four other SNPs
(MMP-1.1, MMP-1.2, MMP-1.3 and MMP-1.4) in the promoter
region are not correlated with gastric cancer occurrence,
suggesting these promoter variants to be low penetrance risk
factors in gastric cancer. The mitogen-activated protein kinase
signaling pathway regulates MMP-1 gene expression by activating
cofactors that interact with AP1 and polyoma-enhancing activity–
3/E26 virus (PEA3/Ets) transcription factor-binding sites located
within the promoter region [38]. It is well known that the 2G type
of SNP at 21607 (MMP-1.1) in the promoter of MMP-1 creates a
core recognition sequence (59-GGAT-39) that represents the
binding site for Ets family transcription factors. The promoter
containing the 2G allele displays significantly higher transcrip-
tional activity than the 1G allele in normal fibroblasts and
melanoma cells [13]. Also, Ets transcription factors can positively
and negatively activate transcription by interaction with coregu-
latory-binding partners or by regulating phosphorylation [38].
This suggests that the Ets family proteins and partner proteins may
differ in various cell types [38]. Alternatively, other pathways
regulating MMP-1 expression may act independently of the SNP
at 21607 bp [39]. Similar results for MMP-1.1 polymorphism
have been reported in other investigations on gastric cancer using
Japanese populations, gastric cardiac adenocarcinoma (GCA) in a
Chinese population, and prostate cancer in a Turkish population.
However contradictory results have been reported in other
investigations on colorectal cancer using Japanese, Korean and
Figure 2. Haplotype effect on serum MMP-1 concentration. Serum MMP-1 level in patients with lower stomach cancer with risk haplotypes
(n = 54), and upper stomach cancer with non risk haplotypes (n = 15) were compared by ELISA. Results showed patients with lower stomach cancer
exhibit a 1.43 fold higher MMP-1 level than in upper stomach cancer patients (p,0.05 by t-test) (box whisker diagram).
doi:10.1371/journal.pone.0088040.g002
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Italian populations [15–17,30,31,40]. The 2G allele appears to be
more frequently identified in Asian populations than in European
populations [16,30,41], and this is also supported by our data.
These discordant results may be a consequence of the number of
subjects, the ethnicity of the population and the source of DNA
(tumor derived compared to normal genomic) [20].
Patients having combination of the TA and TT genotype for
MMP-1.3 polymorphism, a combination of the TC and CC
genotype for MMP-1.4 polymorphism, and a combination of the
TC and CC genotype for MMP-1.5 polymorphism are at more
risk of lower stomach cancer (lower & middle body, antrum and
pylorus of stomach), suggesting that these three polymorphisms,
separately or in combination may be used as a marker for
diagnosing and treating patients having lower stomach cancer in
our population. In India, a trend towards an increase in the
incidence of cardia tumors (upper stomach cancer) was observed
from different cancer registries. Contradictory results were found
for our population showing higher incidence of noncardia cancers
(lower stomach cancer) (64%) suggesting Indian cancer registries
may have inadequate data regarding eastern Indian populations,
especially for the region of West Bengal, Bihar and Orissa.
Further, these observed differences between gastric cancers by
anatomic site and risk of lower stomach cancer incidence with
respect to three adjacent SNPs near the transcription start site of
the MMP-1 gene suggest that they are distinct diseases with
different epidemiological etiologies which may be governed by
these polymorphisms in the eastern Indian region. Detailed
epidemiological analyses of their demographic trends and risk
factors in other cancer types in similar populations will help us to
apply new strategies to control cancer. Also, no previous
information is available for these polymorphisms in the occurrence
of gastric cancer. So, further studies need to confirm our findings
in larger sample sizes and in other populations.
In chondrosarcoma, esophageal cancer and melanoma, patients
with increased levels of MMP-1 expression are correlated with a
worse outcome regarding tumor invasion and metastasis [38].
Additionally, the MMP-1.1 2G allele may be implicated in the
differentiation of gastric cancer, lymph node metastasis of breast
cancer, in decreasing the age of onset in male smokers of lung
cancer and tumors with infiltrative growth, and in lymph node
metastases in colorectal cancer [21,30,42,43]. However, stratifi-
cation analyses with respect to gastric cancer progression in our
study shows, those MMP-1 promoter polymorphisms are not
significantly associated with invasion, lymph node metastasis,
distant metastasis and thus TNM classification of gastric cancer,
with some exceptional contradictions. MMP-1.3 polymorphism
which shows a positive significance (p=0.021) for regional lymph
node metastasis having a combination of TA and TT genotype,
suggests that the T allele has a detrimental effect on gastric cancer
progression and early metastasis. MMP-1.4 polymorphism with a
combination of the TC and CC genotype shows a negative
correlation for regional lymph node metastasis in addition to
distant metastasis, contradicting MMP-1.3 polymorphism. Possible
explanations for this observation may reside in the degree of tumor
invasion, further, metastasis in gastric carcinoma might also
determined by the response to growth factors and cytokines
besides the presence of 2G, G, T, C, C alleles (respectively for
MMP-1.1, -1.2, -1.3, -1.4 and -1.5) in the MMP-1 promoter.
Cytokines, such as interleukin-1 (IL-1), influence the expression
levels of MMP-1 and act as growth stimulators correlating with
liver metastasis of gastric carcinoma [44–46]. The MMP-1.1
polymorphism may increase the MMP-1 expression in response to
growth factors and cytokines [47]. Transcriptional regulation is a
complex process that is often influenced by tissue-specific factors.
Although various human tumor tissues have demonstrated co-
expression of Ets factor and MMP-1, there was no correlation
observed between Ets expression and metastasis in pancreatic and
thyroid carcinoma [48,49]. Therefore, it is possible that MMP-1
transcriptional regulation is not directly increased by the presence
of this Ets-binding site [38]. This suggests that gene expression
secondary to MMP-1 SNPs is tissue specific and varies functionally
between different disease processes [38]. So, the presence of
polymorphic alleles of the MMP-1 promoter may not necessarily
contribute to the degree of tumor invasion and in addition to
progression of gastric carcinoma. However, we found a significant
association between the MMP-1.2 polymorphism and the histo-
logical classification. Patients carrying at least one G allele have
showed significantly greater risk for poorly differentiated (PD)
carcinomas (p=0.001). This finding is not observed for other SNPs
in the promoter region. The histological determination of tumor
grade and the subsequent clinical course of gastric cancer is
subjective in nature, and more objective methods have been
unsuccessfully sought to assess prognosis [38].
An increasing number of studies have shown that a disease
phenotype can be associated with a linked loci or haplotype made
up of polymorphisms that are not individually associated with the
phenotype [50]. Functional studies showed that the MMP-1
promoter polymorphisms exert haplotype effects on MMP-1
promoter activity in cancer cells [50]. In our population,
combinations of paired loci of adjacent polymorphisms do not
exert any significant increased or decreased risk for gastric cancer
and a gene-dose effect study confirmed the finding. Our study
showed that the degree of linkage disequilibrium between the
polymorphisms in the MMP-1 gene promoter is substantially low.
The low degree of linkage disequilibrium between the MMP-1
gene polymorphisms likely reflects the presence of recombination
hotspots at this genomic locus. Three of the five polymorphisms,
i.e., MMP-1.2 (rs1144393), MMP-1.3 (rs475007) and MMP-1.4
(rs514921) have been studied in the international HapMap
project, and have been shown to be located near a recombination
hotspot and thus accounted for low LD [24]. We found nearly 16
haplotypes for studied MMP-1 polymorphisms, none of which
contribute a major part in the population. In the MMP-1 gene
promoter, in which linkage disequilibrium between polymor-
phisms is substantially weaker, to partition the different haplotypes
would require the genotyping of four of the five polymorphisms
(MMP-1.1 and MMP-1.5 are in complete linkage). Also the
distribution of haplotypes of all five SNPs between patients and
controls was not found to be differentially distributed, and this may
be due to the possibility that individual SNPs do not exert risk for
the disease. However, we have found a functional correlation of
MMP-1 promoter polymorphic haplotypes with MMP-1 expres-
sion in a locoregional manner of gastric cancer occurrence. Thus it
can be hypothesized that, MMP-1 promoter haplotypes may have
functional importance in regulation of MMP-1 gene transcription,
resulted in altered expression. This suggests MMP-1 functional
polymorphic haplotypes may be a prognostic factor for locore-
gional gastric cancer progression.
To date, most genetic epidemiology studies of MMP-1 gene
variation in relation to cancers have focused on the21607 1G/2G
polymorphism [15–17,30,31,40,41]. The results of our study
indicate a need for genotyping additional polymorphisms in the
MMP-1 gene promoter and undertaking haplotype analysis, as
typing the 21607 1G/2G polymorphism alone cannot fully
segregate the various MMP-1 haplotypes that may differ in
promoter activity. Further studies will be required to determine
the MMP-1 haplotypes and their frequencies in other populations.
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In conclusion, our study suggests that MMP-1.3, MMP-1.4 and
MMP-1.5 polymorphisms in the MMP-1 promoter enhances the
risk of lower stomach tumor formation in an eastern Indian
population. In addition, our results suggest these three adjacent
polymorphisms in the MMP-1 gene promoter to be functionally
important in affecting MMP-1 gene transcription, subsequently
reflected in serum MMP-1 levels. Furthermore, we found that
MMP-1.3 polymorphism contributed to the susceptibility of lymph
node metastasis. However the current study reveals that all these
three SNPs are not independent prognostic parameters to predict
the outcome of patients with gastric cancer. Due to the small
sample size we are unable to find any association of these
polymorphisms with gastric cancer risk. Detailed epidemiological
analyses of these SNPs, demographic trends and risk factors in
other diseases in similar populations in addition to larger sample
sizes are welcome in order to strengthen our findings. Further
research may be helpful to determine whether our observations
are tumor specific or applicable to other adenocarcinomas such as
breast, prostate or lung cancer. Our data might serve a useful
predictive parameter for early identification of individuals at-risk
of lower stomach cancer and could aid strategies to optimize
treatment for a disease such as gastric cancer.
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